MetaCap

Progyny Financial Ratios

NASDAQ: PGNYHealth CareMisc Health and Biotechnology ServicesUSD

27.93+0.10 (+0.36%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Progyny ratio analysis

Progyny earned a net margin of 4.5% in FY 2025, down from 4.7% a year earlier. Gross margin was 23.6% compared with a median of 20.8% over the prior 8 years. Return on equity reached 11.3%, meaning Progyny generated 0.11 dollars of profit for every dollar of shareholders' equity.

At the end of FY 2025, PGNY traded at 39.6 times earnings; across the 6 fiscal years shown, its year-end P/E ranged from 30.9 to 103.8, with a median of 68.1. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

Progyny financial ratios (annual)

Progyny annual financial ratios
RatioFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
P/E ratio (at fiscal year end)39.6030.8859.97103.8376.2990.19———
Price / sales1.711.383.253.658.9610.542.34——
Price / book4.273.816.387.6217.8221.774.70——
Gross margin23.6%21.7%21.9%21.3%22.4%20.3%19.8%18.4%15.2%
Operating margin6.6%5.8%5.7%3.0%6.5%2.4%4.2%-3.3%-22.7%
Net margin4.5%4.7%5.7%3.9%13.1%13.5%-3.7%0.6%-25.6%
Free cash flow margin14.9%14.9%17.0%9.8%4.8%10.2%-2.0%1.6%-20.8%
Return on equity (ROE)11.3%12.9%11.2%8.1%26.1%27.8%-7.5%——
Return on assets (ROA)7.9%9.0%8.2%5.6%18.4%18.3%-5.7%1.6%—
Current ratio2.732.803.442.722.622.453.660.81—
Revenue growth10.4%7.2%38.3%57.2%45.2%50.1%117.9%116.9%—
EPS growth14.0%-8.1%106.7%-54.5%40.4%—-1,125.0%——

Related